Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Status:
Completed

Trial end date:
2020-10-19

Target enrollment:

Participant gender:

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Phase 1

Novartis Pharmaceuticals